Stock CZO CEAPRO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 01:00:57 2024-05-21 pm EDT 		5-day change 1st Jan Change
0.27 CAD 0.00% Intraday chart for Ceapro Inc. 0.00% +42.11%
May. 17 Aeterna Zentaris Finalizes Some Details for Ceapro Merger MT
May. 17 Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 29.66 24.75 51.23 47.39 46.16 14.88
Enterprise Value (EV) 1 28.45 26.18 48.83 42.26 34.97 8.281
P/E ratio -93 x -21.8 x 33 x 16.7 x 10.5 x -3.16 x
Yield - - - - - -
Capitalization / Revenue 2.56 x 1.92 x 3.39 x 2.76 x 2.45 x 1.54 x
EV / Revenue 2.45 x 2.03 x 3.23 x 2.46 x 1.86 x 0.86 x
EV / EBITDA 110 x 22.6 x 13.1 x 10.6 x 5.48 x -1.5 x
EV / FCF -6.76 x 18.1 x 15.1 x 22.3 x 10.8 x -2.59 x
FCF Yield -14.8% 5.53% 6.64% 4.49% 9.22% -38.6%
Price to Book 1.28 x 1.11 x 2.11 x 1.74 x 1.43 x 0.53 x
Nbr of stocks (in thousands) 77,045 77,336 77,621 77,686 78,233 78,293
Reference price 2 0.3850 0.3200 0.6600 0.6100 0.5900 0.1900
Announcement Date 4/11/19 4/16/20 4/22/21 4/13/22 4/12/23 4/29/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 11.59 12.88 15.12 17.2 18.84 9.633
EBITDA 1 0.2586 1.159 3.724 3.985 6.38 -5.517
EBIT 1 -0.3068 -0.326 2.347 2.623 5.499 -6.255
Operating Margin -2.65% -2.53% 15.52% 15.26% 29.19% -64.93%
Earnings before Tax (EBT) 1 -0.9212 -1.136 1.856 2.619 5.777 -5.905
Net income 1 -0.3155 -1.133 1.856 2.842 4.398 -4.71
Net margin -2.72% -8.79% 12.27% 16.53% 23.34% -48.89%
EPS 2 -0.004140 -0.0147 0.0200 0.0366 0.0564 -0.0602
Free Cash Flow 1 -4.207 1.447 3.24 1.898 3.225 -3.2
FCF margin -36.29% 11.24% 21.43% 11.04% 17.12% -33.22%
FCF Conversion (EBITDA) - 124.94% 87.01% 47.62% 50.54% -
FCF Conversion (Net income) - - 174.57% 66.76% 73.32% -
Dividend per Share - - - - - -
Announcement Date 4/11/19 4/16/20 4/22/21 4/13/22 4/12/23 4/29/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 1.43 - - - -
Net Cash position 1 1.21 - 2.4 5.13 11.2 6.6
Leverage (Debt/EBITDA) - 1.234 x - - - -
Free Cash Flow 1 -4.21 1.45 3.24 1.9 3.22 -3.2
ROE (net income / shareholders' equity) -1.38% -4.98% 7.96% 11% 14.7% -15.7%
ROA (Net income/ Total Assets) -0.72% -0.77% 5.19% 5.49% 9.99% -11.3%
Assets 1 43.72 146.2 35.75 51.79 44.01 41.67
Book Value Per Share 2 0.3000 0.2900 0.3100 0.3500 0.4100 0.3600
Cash Flow per Share 2 0.0200 0.0200 0.0700 0.1000 0.1800 0.1100
Capex 1 1.26 0.34 0.62 0.71 0.34 0.98
Capex / Sales 10.83% 2.63% 4.09% 4.12% 1.81% 10.18%
Announcement Date 4/11/19 4/16/20 4/22/21 4/13/22 4/12/23 4/29/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CEAPRO INC. Stock Ceapro Inc.
+42.11% 15.53M
MODERNA, INC. Stock Moderna, Inc.
+44.48% 54.04B
LONZA GROUP AG Stock Lonza Group AG
+43.57% 41.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.86% 41.92B
CELLTRION, INC. Stock Celltrion, Inc.
-7.59% 28.35B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.30% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.83% 19B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.15% 13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.40% 12.28B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.15% 12.19B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CZO Stock
  4. Financials Ceapro Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW